.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Limited-stage small cell lung cancer (LS-SCLC) remains an aggressive malignancy that frequently recurs despite radical therapy. Recent data from a phase 2 clinical trial investigate the role of durvalumab in LS-SCLC when integrated directly with concurrent chemoradiotherapy (cCRT). While immunotherapy has revolutionized extensive-stage disease, its optimal timing in limited-stage settings remains a subject of intense clinical scrutiny.
In this single-arm study, 51 patients underwent a regimen of etoposide and platinum-based chemotherapy combined with durvalumab. Patients received thoracic radiotherapy concurrently with the chemoimmunotherapy cycles. Results showed a median progression-free survival (PFS) of 17.0 months. The 1-, 2-, and 3-year PFS rates were 56.9%, 35.9%, and 28.2%, respectively. Furthermore, the median overall survival (OS) reached 32.0 months. These survival outcomes suggest that adding durvalumab during the radiation phase is feasible and provides encouraging efficacy.
Safety is a primary concern when combining thoracic radiation with PD-L1 inhibitors. In this trial, 33.4% of patients experienced grade 3 or 4 adverse events. Specifically, seven cases involved immune-related events. However, the cohort generally tolerated the treatment well. Consequently, these findings support the continued investigation of concurrent immunotherapy in patients eligible for radical chemoradiotherapy.
This trial adds to the growing body of evidence regarding immune checkpoint inhibitors in LS-SCLC. While the landmark ADRIATIC trial established durvalumab as a standard for consolidation therapy, the concurrent approach tested here aims to maximize the synergistic effects of radiation and immunotherapy. Moreover, physicians should monitor for potential pulmonary toxicity, although current results are promising.
The study reported 3-year progression-free survival (PFS) and overall survival (OS) rates of 28.2% and 49.6%, respectively, with a median OS of 32.0 months.
The treatment was well tolerated. Approximately 33.4% of patients experienced grade 3 or 4 adverse events, but immune-related toxicities were manageable with standard care.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A phase 2 trial indicates that adding durvalumab to concurrent chemoradiotherapy in LS-SCLC is well-tolerated and shows encouraging efficacy outcomes....
4 months ago
A Bayesian network meta-analysis evaluated non-surgical treatments for benign thyroid nodules, finding thermal ablation techniques like laser and radiofrequency ablation superior in nodule volume reduction, whereas levothyroxine showed the strongest TSH suppression without significant changes in FT3 or FT4.
Today
A retrospective study demonstrates that deep learning models using longitudinal digital breast tomosynthesis significantly enhance 5-year breast cancer risk prediction compared to single-timepoint imaging and clinical models.
Today
Researchers developed poly(trimethylene carbonate)-based polymersomes loaded with L-arginine for ROS-triggered nitric oxide release. This mild, stable nano-delivery system produces gas in response to hydrogen peroxide, offering a promising, targeted platform for cardiovascular, surgical, and oncological therapy.
Today
Researchers developed a Haversian-inspired composite scaffold that addresses delayed vascularization and wet-state mechanical deterioration in critical bone defect repair. By integrating spatially programmed calcium phosphate minerals and selective silica reinforcement, the design promotes vascularized bone repair.
Yesterday
A landmark study analyzing over 56,000 adult health records in Delhi-NCR reveals that hypertension and diabetes coexistence affects nearly 5% of adults. The prevalence doubles expected rates and rises sharply after age 40. Early integrated screening is essential to prevent microvascular and macrovascular complications.
Today
